Skip to content
DataLookout
Menu

NCT07768345

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 17 → 21 locations
  2. Minor Trial sites expanded: 10 → 17 locations
  3. Notable Eligibility criteria expanded, about 10 words
    • Trial sites expanded: 5 → 10 locations
  4. Notable Recruitment opened
    • Trial sites expanded: 1 → 5 locations
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of participants reporting local reactions
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting systemic events
Timeframe: For up to 7 days after vaccination
Percentage of participants reporting adverse events
Timeframe: Through 1 month after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions
Timeframe: Through 12 months after vaccination
Percentage of participants reporting serious adverse events
Timeframe: Through 12 months after vaccination
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)
Timeframe: Before vaccination, 1 month, 6 months and 12 months after vaccination
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
Timeframe: Before vaccination, 1 month, 6 months and 12 months after vaccination

Secondary (1)

Seroresponse rate of NTs for RSV A and RSV B

Arms and interventions

Group 1Experimental

RSVpreF Vaccine

Group 2Experimental

RSVpreF Vaccine

Group 3Experimental

RSVpreF Vaccine

Group 4Experimental

RSVpreF Vaccine

Biologicals: RSVpreF Vaccine

Sites

21 sites in 1 country